Ranking Patient-Reported Outcome Measures for Patients With PsA

In measuring disease activity among patients with psoriatic arthritis (PsA), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), clinical Disease Activity of PsA (cDAPSA), and Psoriatic Arthritis Impact of Disease 12-item (PsAID12) questionnaire continue to rank superior, according to the results of a recent study published in Arthritis Care Research.

The objective of the study was “to determine the responsiveness to therapy and minimum clinically important improvement (MCII) for patient-reported outcome measures in PsA and to examine the impact of baseline disease activity on the ability to demonstrate change.”

The longitudinal cohort study included 171 patients and 266 therapy courses. The mean age was 51 years, and more than half of the population were women. The mean swollen joint counts were 3 and tender joint counts were 6.

In general, SRMs and MCII for all measures were small to moderate. However, they were greater among patients with higher baseline disease activity. But BASDAI, cDAPSA, and PsAID12 had good sensitivity to change in disease activity among patients throughout, both at low and high baseline disease activity.

“In future pragmatic trials, selection of measures should take into account the projected baseline disease activity of patients enrolled,” the team noted.

Reference:
Karmacharya P, Stull C, Stephens-Shields A et al. Responsiveness and minimum clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis: A prospective cohort study. Arthritis Care Res. Published online: March 13, 2023. DOI: 10.1002/acr.25111.